Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy

Kim, Doyoung; Kang, Yong-Myung; Cho, Hyun-Kyu; Park, Seo-Jeong; Lee, Myoung-Heon; Lee, Youn‐Jeong; Kang, Hyun-Mi

doi:10.1016/j.vaccine.2021.08.089

Cited by 7 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, recombinant vaccine by reverse genetics which contain PR8 back-boned virus is known to be more easily replicated and proliferative in cell and egg culture systems [ 38 , 39 ]. Similarly, our previous studies demonstrated that rgH9N2/PR8 reassortant viruses show high productivity (10 8.3 to 10 9.1 EID 50 /0.1 mL) [ 26 , 28 ]. Likewise, vac564, developed by multiple passage in eggs, also showed high productivity (10 8.4 EID 50 /0.1 mL and 1024 HA units at passage 30 (CE30)).…”

Section: Discussionsupporting

confidence: 61%

“…In one study, they showed mortality with 15 birds dying in 1 day and reducing egg production from 10 to 27% in the field [ 24 ]. Hence, a recombinant vaccine candidate against Y280 lineage virus (rgHS314) was developed in Korea [ 26 , 27 ].…”

Section: Introductionmentioning

confidence: 99%

“…Current vaccine research aims to reduce the cost and difficulty of production of current inactivated vaccines, while also increasing efficacy and providing broad protection against multiple H9N2 subtypes [ 2 ]. Recent studies report development of H9N2 recombinant vaccines generated by reverse genetics; these vaccines contain the internal genes of the high yield PR8 strain (A/Puerto Rico/8/34 (H1N1) [ 26 , 28 ]. Additionally, H9N2 vectored vaccines based on Newcastle disease virus, fowl pox virus, and turkey herpesvirus have been developed [ 29 , 30 , 31 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Protection of SPF Chickens by H9N2 Y439 and G1 Lineage Vaccine against Homologous and Heterologous Viruses

et al. 2023

Self Cite

View full text Add to dashboard Cite

Prior to the identification of low pathogenic avian influenza H9N2 viruses belonging to the Y280 lineage in 2020, Y439 lineage viruses had been circulating in the Republic of Korea since 1996. Here, we developed a whole inactivated vaccine (vac564) by multiple passage of Y439 lineage viruses and then evaluated immunogenicity and protective efficacy in specific-pathogen-free chickens. We found that LBM564 could be produced at high yield in eggs (108.4EID50/0.1 mL; 1024 hemagglutinin units) and was immunogenic (8.0 ± 1.2 log2) in chickens. The vaccine showed 100% inhibition of virus in the cecal tonsil with no viral shedding detected in either oropharyngeal or cloacal swabs after challenge with homologous virus. However, it did not induce effective protection against challenge with heterologous virus. An imported commercial G1 lineage vaccine inhibited viral replication against Y280 and Y439 lineage viruses in major tissues, although viral shedding in oropharyngeal and cloacal swabs was observed up until 5 dpi after exposure to both challenge viruses. These results suggest that a single vaccination with vac564 could elicit immune responses, showing it to be capable of protecting chickens against the Y439 lineage virus. Thus, our results suggest the need to prepare suitable vaccines for use against newly emerging and re-emerging H9N2 viruses.

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Protection of SPF Chickens by H9N2 Y439 and G1 Lineage Vaccine against Homologous and Heterologous Viruses

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Unfortunately, as the Y280 lineage of H9N2 AIV was newly introduced into South Korea in 2020, previously authorized vaccines against the Y439 lineage of H9N2 AIV may not be an appropriate option to control the current Y280 lineage of H9N2 AIV because of the difference in the genetic and antigenic features (81.8% nucleotide similarity) [ 108 ]. In animal experiments, the Y439 lineage of the vaccine showed only limited efficacy to heterogeneous Y280 lineage of H9N2 AIV (Y439 lineage of the vaccine reduced the replication of the Y280 lineage of H9N2 AIV in the cecal tonsils by 37.5%, and also partially inhibits viral shedding in respiratory and intestinal tracts) ( Fig.…”

Section: Control Strategies Of H9n2 Ai In South Koreamentioning

confidence: 99%

“…By contrast, the rgHS314 virus (derived from A/chicken/Korea/H314/2020), which was newly developed as an autogenous vaccine for the current epizootic Y280 lineage of H9N2 AIV, can reduce viral replication significantly with 100% inhibition of virus recovery in the cecal tonsil and no viral shedding in OP and CL swabs ( Fig. 5 ) [ 108 ]. New commercial vaccines using the Y280 lineage of the H9N2 vaccine seed strain may be available in the field in the first half of 2023.…”

Section: Control Strategies Of H9n2 Ai In South Koreamentioning

confidence: 99%

Current situation and control strategies of H9N2 avian influenza in South Korea

Sagong

Lee

et al. 2023

J Vet Sci

Self Cite

View full text Add to dashboard Cite

The H9N2 avian influenza (AI) has become endemic in poultry in many countries since the 1990s, which has caused considerable economic losses in the poultry industry. Considering the long history of the low pathogenicity H9N2 AI in many countries, once H9N2 AI is introduced, it is more difficult to eradicate than high pathogenicity AI. Various preventive measures and strategies, including vaccination and active national surveillance, have been used to control the Y439 lineage of H9N2 AI in South Korea, but it took a long time for the H9N2 virus to disappear from the fields. By contrast, the novel Y280 lineage of H9N2 AI was introduced in June 2020 and has spread nationwide. This study reviews the history, genetic and pathogenic characteristics, and control strategies for Korean H9N2 AI. This review may provide some clues for establishing control strategies for endemic AIV and a newly introduced Y280 lineage of H9N2 AI in South Korea.

show abstract

Live recombinant Newcastle disease virus vectored vaccine expressing the haemagglutinin of H9N2 avian influenza virus suppresses viral replication in chickens

et al. 2022

View full text Add to dashboard Cite

Development of a recombinant H9N2 influenza vaccine candidate against the Y280 lineage field virus and its protective efficacy

Cited by 7 publications

References 12 publications

Protection of SPF Chickens by H9N2 Y439 and G1 Lineage Vaccine against Homologous and Heterologous Viruses

Protection of SPF Chickens by H9N2 Y439 and G1 Lineage Vaccine against Homologous and Heterologous Viruses

Current situation and control strategies of H9N2 avian influenza in South Korea

Live recombinant Newcastle disease virus vectored vaccine expressing the haemagglutinin of H9N2 avian influenza virus suppresses viral replication in chickens

Contact Info

Product

Resources

About